Validation and Impact of Cardiorespiratory Fitness in Severe Mental Illness - the Heart in Mind Project
Launched by BJORN H. EBDRUP · Dec 16, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Heart in Mind Project is a clinical trial that aims to understand how to measure physical fitness in people with severe mental illnesses, such as schizophrenia and bipolar disorder. The study will include 50 participants with these mental health conditions and 25 healthy individuals to compare results. Participants will undergo three different tests to evaluate their fitness levels during an initial visit and will then be monitored for their physical activity over 14 days.
To participate, individuals with severe mental illness must be between 18 and 45 years old, currently receiving antipsychotic medication for at least a month, and able to provide informed consent. Healthy participants will also need to be in the same age range but should have no psychiatric diagnosis or family history of mental illness. This study is currently recruiting participants, and those who join can expect to contribute to important research that may improve how fitness is assessed and managed in people with severe mental illnesses.
Gender
ALL
Eligibility criteria
- • Patients
- Inclusion Criteria:
- • 1) 18-45 years; 2) Diagnosis within schizophrenia spectrum or affective disorders (i.e. F2.x or F3.x according to ICD-10 classification); 3) current antipsychotic treatment for more than one month on a regular daily dose and 4) Able to give informed consent.
- Exclusion Criteria:
- • 1) Clinical or laboratory evidence of uncompensated medical disease; 2) Unstable psychiatric disorder; 3) Acute suicidal risk; 4) Planned hospitalization within the study period.
- • Healthy controls
- Inclusion Criteria:
- • 1) 18-45 years; 2) No psychiatric diagnosis or having first-degree relatives with psychiatric diagnoses; 3) able to give informed consent.
- Exclusion Criteria:
- • 1) Clinical or laboratory evidence of uncompensated medical disease; 2) Indication of psychiatric disorder.
About Bjorn H. Ebdrup
Bjorn H. Ebdrupe is a dedicated clinical trial sponsor with a focus on advancing innovative therapeutic solutions through rigorous research and development. With a commitment to enhancing patient outcomes, Ebdrupe oversees a portfolio of clinical trials designed to evaluate the safety and efficacy of novel treatments across various therapeutic areas. Leveraging a collaborative approach, Ebdrupe engages with leading researchers, healthcare professionals, and regulatory bodies to ensure the highest standards of compliance and scientific integrity. Their mission is to bridge the gap between cutting-edge science and clinical practice, ultimately contributing to the betterment of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glostrup, , Denmark
Patients applied
Trial Officials
Bjørn H Ebdrup, Professor and psychiatrist
Study Director
Mental Health Center Glostrup, Center for Neuropsychiatric Schizophrenia Research
Victor Sørensen, PhD student
Principal Investigator
Mental Health Center Glostrup, Centre for Applied Research in Mental Health Care & Center for Neuropsychiatric Schizophrenia Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported